Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

To join this study, participants need to have a specific type of multiple sclerosis called Relapsing-remitting MS (RRMS), as confirmed by certain medical guidelines. Your disability level, measured on a scale from 0 to 5.5, should fall within these numbers. You also need to show signs that your MS has been active recently, and you shouldn't have had a flare-up (relapse) for at least 28 days before starting the study.

You cannot join if you have other types of MS, such as primary progressive or secondary progressive MS. There are also specific rules about how long you've had MS and your current disability level. The study team will need to check if you have any other significant health conditions that might require long-term treatment with certain medications, or if you are taking any medicines that might interfere with the study.

Finally, if you have any medical conditions that would make it unsafe for you to take the study medicine or go through the study procedures, or if certain blood test results are outside the normal range, you would not be able to take part. The study is open to both men and women aged 18 to 99 years.

Taking part in this study would involve regular visits to the clinic over a period of time. During these visits, you would receive the study medication, either ABP 692 or Ocrevus, and the study team would monitor your health carefully. You would have physical examinations, blood tests, and special brain scans (MRIs) at specific times throughout the study to check how the treatment is working and monitor for any side effects. The study aims to look at your brain scans over 24 weeks to see the effects on new active brain lesions. More detailed information on the exact number of visits and the full duration of the study would be provided by the research team.